Literature DB >> 23161395

Urinary metabolites after intravenous propofol bolus in neonates.

Anne Smits1, Rene Verbesselt, Aida Kulo, Gunnar Naulaers, Jan de Hoon, Karel Allegaert.   

Abstract

In neonates, propofol mainly undergoes hydroxylation to quinol metabolites with only limited glucuronidation. The aim of this study is to search for covariates of neonatal propofol biotransformation based on 24 h urine collections. In neonates receiving an intravenous propofol bolus for short procedural sedation, urine was collected during 24 h. Urinary propofol metabolites [propofol glucuronide (PG), 1- and 4-quinol glucuronide (QG)] were determined using high-performance liquid chromatography after a dual-step solid phase extraction combined with ultraviolet and fluorescence detection. Propofol metabolites, their contribution to total metabolite elimination and propofol glucuronide/quinol glucuronide (PG/QG) ratio were determined. The impact of continuous [postmenstrual age (PMA), postnatal age (PNA), body weight, propofol dose, creatinaemia] and dichotomous variables [PNA ≤ 7 days (yes/no), PNA ≥ 10 days (yes/no), hyperbilirubinaemia (yes/no), cardiopathy (yes/no)] on PG/QG ratio and on patients with low (≤10 %) vs. high (>10 %) urinary PG recovery were examined. Thirty-two neonates were included. Median total propofol metabolite recovery was 40.95 (2.01-129.81) % with PG/QG ratio 0.44 (0.01-5.93). PNA (dichotomous 7 days as well as 10 days) was a significant covariate of PG/QG ratio. Late PNA more frequently resulted in high urinary PG fraction. Significance was more pronounced with PNA 10 days as cut-off point for early neonatal life compared to 7 days. Age 10 days is pivotal in early life propofol metabolism. This confirms earlier documented propofol clearance studies. This is the first report of the modified quantification assay used to determine urinary propofol metabolites in neonates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23161395     DOI: 10.1007/s13318-012-0109-6

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  High-performance liquid chromatographic assay to detect hydroxylate and conjugate metabolites of propofol in human urine.

Authors:  P Favetta; J Guitton; C S Degoute; L Van Daele; R Boulieu
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-05-26

2.  Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates?

Authors:  Anne Smits; Roosmarijn F W De Cock; Veerle Cossey; Catherijne A J Knibbe; Karel Allegaert
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

3.  Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia.

Authors:  Irena Loryan; Marja Lindqvist; Inger Johansson; Masahiro Hiratsuka; Ilse van der Heiden; Ron H N van Schaik; Jan Jakobsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2011-10-18       Impact factor: 2.953

4.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

5.  The pharmacokinetics of intravenous paracetamol in neonates: size matters most.

Authors:  Karel Allegaert; Greta M Palmer; Brian J Anderson
Journal:  Arch Dis Child       Date:  2011-02-13       Impact factor: 3.791

6.  Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man.

Authors:  T B Vree; A J Lagerwerf; C P Bleeker; P M de Grood
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-01-22

Review 7.  Propofol and children--what we know and what we do not know.

Authors:  Ann E Rigby-Jones; J Robert Sneyd
Journal:  Paediatr Anaesth       Date:  2010-11-18       Impact factor: 2.556

8.  In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age.

Authors:  Karel Allegaert; Sophie Vanhaesebrouck; Rene Verbesselt; John N van den Anker
Journal:  Ther Drug Monit       Date:  2009-08       Impact factor: 3.681

9.  Recovery and long-term renal excretion of propofol, its glucuronide, and two di-isopropylquinol glucuronides after propofol infusion during surgery.

Authors:  C Bleeker; T Vree; A Lagerwerf; E Willems-van Bree
Journal:  Br J Anaesth       Date:  2008-06-05       Impact factor: 9.166

10.  Propofol metabolites in man following propofol induction and maintenance.

Authors:  P Favetta; C S Degoute; J P Perdrix; C Dufresne; R Boulieu; J Guitton
Journal:  Br J Anaesth       Date:  2002-05       Impact factor: 9.166

View more
  2 in total

Review 1.  Neonatal clinical pharmacology.

Authors:  Karel Allegaert; Marc van de Velde; John van den Anker
Journal:  Paediatr Anaesth       Date:  2013-04-26       Impact factor: 2.556

Review 2.  Neonatal pain management: still in search for the Holy Grail.

Authors:  Karel Allegaert; John N van den Anker
Journal:  Int J Clin Pharmacol Ther       Date:  2016-07       Impact factor: 1.366

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.